Long-term peginterferon monotherapy following 72 weeks of peginterferon and ribavirin in hepatitis C genotype-1 infected slow responders

Long-term peginterferon monotherapy following 72 weeks of peginterferon and ribavirin in hepatitis C genotype-1 infected slow responders - Long-term peginterferon monotherapy following peginterferon and ribavirin in chronic hepatitis C

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013069

Enrollment

Registered

2014-02-05

Start date

2005-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis C

Interventions

patients with peginterferon monotherapy following 72 weeks of peginterferon and ribavirin Patients with 72 weeks of peginterferon and ribavirin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with chronic HCV genotype 1 infection received 72 weeks of combined therapy for Peg-IFN and RBV. Serum HCV RNA levels were > 100,000 IU/mL at baseline. Serum HCV RNA became undetectable 13&#8211;44 weeks after the start of therapy, and serum HCV RNA remained undetectable after 72 weeks of treatment.

Exclusion criteria

Exclusion criteria: Case that was complicated with a malignant tumor Cirrhosis case of the decompensation period

Design outcomes

Primary

Measure	Time frame
Sustained virological response	—

Countries

Japan

Contacts

Public Contactshinya watanabe

Hamamatsu University School of Medicine Division of Hepatology

shinya5413@tc4.so-net.ne.jp053-435-2263

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026